Ralph Kern

Ralph Kern

Company: Brainstorm Cell Therapeutics

Job title: President & Chief Medical Officer

Seminars:

Chair’s Closing Remarks 5:00 pm

Read more

day: Day One

Advancing Novel CSF Biomarkers to Evaluate ALS Target Engagement & Improve Therapeutic Outcomes 9:30 am

CSF biomarkers interrogate multiple neuroinflammatory, neurodegenerative and neuroprotection pathways to confirm target engagement Employing biomarkers at baseline and on-treatment in combination with clinical variables to predict clinical responders Supporting biobanks and continuing dialogue with regulators to advance adoption of novel biomarkersRead more

day: Day One

Chair’s Opening Remarks 8:25 am

Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.